UCMYM 802
Alternative Names: Anti-MSLN CAR+ T cell; MSLN CAR-T cRNA - UTC Therapeutics; UCMYM-802Latest Information Update: 23 Feb 2024
At a glance
- Originator UTC Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Jan 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV) (NCT06256055)